+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID05644431

Study of Immune Changes in Tumor Environment During Standard Chemotherapy for Localized and Resectable Gastric and Gastroesophageal Junction Cancers

Led by Centre Leon Berard · Updated on 2023-08-30

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the immune tumor microenvironment in patients with localized and resectable gastric and gastroesophageal junction adenocarcinomas undergoing standard neoadjuvant chemotherapy. The study is a prospective, monocentric, interventional cohort trial aiming to understand immune changes and minimal residual disease during treatment both before and after surgery. Participants receive standard chemotherapy as part of their usual care for localized gastric or gastroesophageal junction cancers. The study monitors the immune environment of tumors and lymph nodes through tissue samples collected before treatment, during surgery, and after chemotherapy. The research involves detailed molecular and cellular analyses to track immune cell behavior over time. During the study, participants will have tissue and blood samples collected for immune profiling, including advanced molecular techniques like single-cell RNA sequencing and flow cytometry. Outcomes include describing the immune tumor microenvironment and its evolution over at least 36 months post-inclusion. Patients are closely monitored during their standard treatment, with the study aiming to reveal immune factors influencing response to therapy.

CONDITIONS

Brief Title

GastrOesophageal Tumor, Immune Microenvionnment (GOTIM)

Research Team

C

Clélia COUTZAC, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here